Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18629717 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | April 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18436484 | CARBONIC ANHYDRASE IX TARGETING AGENTS AND METHODS | February 2024 | June 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18428432 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | January 2024 | June 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18571259 | ORAL CARE COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOF | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18548546 | COMPOUND TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN, AND PREPARATION METHOD AND APPLICATION THEREOF | August 2023 | December 2023 | Allow | 4 | 0 | 0 | No | No |
| 18349833 | METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDURE | July 2023 | July 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18137721 | Nanoparticle Photoacoustic Imaging Agents | April 2023 | May 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18108464 | ENCAPSULATION OF MICROBUBBLES WITHIN THE AQUEOUS CORE OF MICROCAPSULES | February 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18163000 | TARGETING LIGANDS FOR TAU PATHOLOGY | February 2023 | December 2024 | Allow | 22 | 1 | 0 | No | No |
| 18100953 | Bismuth-Gadolinium Nanoparticles | January 2023 | April 2025 | Allow | 27 | 2 | 0 | No | No |
| 18081916 | POLYDOPAMINE DECORATED TOBACCO MOSAIC THERANOSTIC VIRUS NANOPARTICLES | December 2022 | November 2024 | Allow | 23 | 1 | 0 | No | No |
| 17990347 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18055100 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | November 2022 | June 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18049288 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | October 2022 | June 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17892203 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER | August 2022 | May 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17809810 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | June 2022 | November 2023 | Allow | 16 | 2 | 0 | No | No |
| 17847194 | PARTICLES FOR USE IN HYPERPOLARIZATION | June 2022 | April 2025 | Allow | 33 | 3 | 1 | No | No |
| 17842418 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | June 2022 | February 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17830165 | LIPID MICROBUBBLES AND PROCESS OF MAKING THEREOF | June 2022 | June 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17827560 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17744128 | COMPOSITIONS COMPRISING HYPERPOLARIZED PROBES FOR H2O2 SENSING AND METHODS OF USING SAME | May 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17662574 | SILICONE-BASED DYES WITH SHORT WAVELENGTH INFRARED ABSORPTION AND EMISSION AND METHODS FOR MAKING AND USING THE SAME | May 2022 | February 2025 | Allow | 34 | 2 | 1 | No | No |
| 17739031 | TARGETING LIGANDS FOR TAU PATHOLOGY | May 2022 | November 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17736957 | LOW X-RAY ATTENUATION CHANGE HARD SHELLED ORAL CONTRAST MATERIAL | May 2022 | June 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17714251 | TARGETED NANO-PHOTOMEDICINES FOR PHOTODYNAMIC THERAPY OF CANCER | April 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17657028 | SURFACTANT MICROBUBBLES AND PROCESS FOR PREPARING AND METHODS OF USING THE SAME | March 2022 | September 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17686962 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17652037 | COMPOSITIONS AND METHODS FOR ASSESSING GUT FUNCTION | February 2022 | April 2024 | Allow | 25 | 2 | 0 | No | No |
| 17552984 | Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer | December 2021 | December 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17523911 | Novel Contrast Agents and Imaging Methods for Early Detection of Diseases | November 2021 | November 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17497119 | MAGNETIC TRACER COMPOSITIONS | October 2021 | August 2023 | Allow | 22 | 4 | 0 | No | No |
| 17403058 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | August 2021 | May 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17368272 | REAGENT FOR BIOCONJUGATION VIA IRREVERSIBLE REBRIDGING OF DISULFIDE LINKAGES | July 2021 | October 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17352773 | TARGETED GAS-FILLED MICROVESICLES FORMULATION | June 2021 | April 2024 | Allow | 34 | 2 | 0 | No | No |
| 17311299 | FLUOROUS METAL CHELATES COMPOSITIONS | June 2021 | January 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17319912 | VEGETABLE OIL-DERIVED CONTRAST AGENT WITH HIGH STABILITY AND PREPARATION METHOD THEREOF | May 2021 | June 2024 | Allow | 37 | 4 | 0 | No | No |
| 17293176 | BISMUTH METAL-ORGANIC FRAMEWORKS FOR USE AS X-RAY COMPUTED TOMOGRAPHY CONTRAST AGENTS | May 2021 | December 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17245938 | RADIOFLUORINATED GPC3-BINDING PEPTIDES FOR PET IMAGING OF HEPATOCELLULAR CARCINOMA | April 2021 | November 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17234323 | BI-DOTA COMPLEX-LOADED DENDRITIC POLYMER NANOPARTICLES | April 2021 | August 2024 | Allow | 40 | 2 | 1 | No | No |
| 17285717 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | April 2021 | March 2022 | Allow | 11 | 0 | 0 | No | No |
| 17224492 | MOLECULAR SENSORS WITH MODIFIED LIGANDS | April 2021 | January 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17211481 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | March 2021 | February 2023 | Allow | 23 | 1 | 1 | No | No |
| 17204524 | NANOPARTICLE-ALGINATE GELS FOR X-RAY IMAGING OF THE VASCULATURE | March 2021 | January 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17275978 | Alpha Emitter Compositions And Methods | March 2021 | November 2024 | Allow | 44 | 3 | 1 | No | No |
| 17196036 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | March 2021 | May 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17191713 | COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABINOID RECEPTORS | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17272636 | COMPOSITION FOR DETECTING HYDROGEN SULFIDE OR MEASURING HYDROGEN SULFIDE CONCENTRATION AND COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR DIAGNOSING OR IMAGING IN VIVO INFLAMMATION, TISSUES HAVING HYPOXIC DAMAGE, OR CANCER | March 2021 | March 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17169455 | PLATINUM SULFIDE PROTEIN NANOPARTICLE HAVING NEAR-INFRARED PHOTOTHERMAL EFFECT AND MULTI-MODAL IMAGING FUNCTION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | February 2021 | May 2022 | Allow | 15 | 1 | 0 | No | No |
| 17265850 | METHOD FOR DIAGNOSIS OF DOPAMINERGIC AND MOVEMENT DISORDERS | February 2021 | October 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17162126 | TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITION | January 2021 | May 2021 | Allow | 3 | 1 | 0 | Yes | No |
| 17158332 | Affinity Magnetic Particles For Imaging System | January 2021 | July 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17248340 | AGGREGATION-INDUCED EMISSION LUMINOGENS FOR PHOTODYNAMIC THERAPY | January 2021 | September 2023 | Allow | 32 | 3 | 1 | No | No |
| 17150488 | FLUORESCENCE IMAGING METHOD AND SYSTEM | January 2021 | April 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17257387 | REAGENT AND PROCESS FOR THE SITE-SPECIFIC DEOXYFLUORINATION OF PEPTIDES | December 2020 | September 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17129490 | POLYDOPAMINE DECORATED TOBACCO MOSAIC THERANOSTIC VIRUS NANOPARTICLES | December 2020 | July 2022 | Allow | 19 | 1 | 0 | No | No |
| 17126340 | MRI CONTRAST AGENT INCLUDING T1 CONTRAST MATERIAL COATED ON SURFACE OF NANOPARTICLE SUPPORT | December 2020 | February 2025 | Allow | 50 | 3 | 1 | Yes | No |
| 17252100 | EMULSION FOR ULTRASOUND ABLATION SURGERY | December 2020 | November 2024 | Allow | 47 | 3 | 1 | No | No |
| 17251786 | Composition Containing a Somatostatin Analogue for Radiopharmaceutical Use | December 2020 | February 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17111953 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | December 2020 | April 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17104859 | DYE AGGREGATES-CONTAINING NANOPARTICLES AND USES THEREOF | November 2020 | December 2023 | Abandon | 37 | 2 | 1 | No | No |
| 17103366 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | November 2020 | September 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17093155 | Ultrasound Gel Composition | November 2020 | September 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17053702 | BIO-BASED MATERIAL WITH ANTIBACTERIAL EFFECT AND USE THEREOF | November 2020 | May 2025 | Allow | 54 | 4 | 0 | Yes | No |
| 17050897 | VITAMIN E DERIVATIVES AND THEIR USE AS MULTI-SCALE IMAGING AGENTS | October 2020 | November 2022 | Abandon | 25 | 2 | 0 | No | No |
| 17050121 | Intranasal Delivery of Fluorescent Marker | October 2020 | October 2024 | Abandon | 48 | 2 | 1 | No | No |
| 17046385 | NOBLE METAL-COATED MECHANORESPONSIVE VESICLES | October 2020 | December 2024 | Abandon | 50 | 3 | 0 | No | Yes |
| 17065319 | COLOR-CODED AND SIZED LOADABLE POLYMERIC PARTICLES FOR THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS AND METHODS OFPREPARING AND USING THE SAME | October 2020 | April 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17060059 | PH and Oxygen dual-sensitive magnetic resonance imaging contrast agent and preparation method thereof | September 2020 | May 2022 | Abandon | 19 | 3 | 0 | No | No |
| 17042408 | PYCLEN-BASED MACROCYCLIC LIGANDS, CHELATES THEREOF AND USES THEREOF | September 2020 | June 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 16982856 | NOVEL COMPOUND, ANTIINFLAMMATORY DRUG COMPRISING THE COMPOUND AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING THE COMPOUND | September 2020 | March 2024 | Allow | 42 | 4 | 0 | No | No |
| 16979017 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | September 2020 | November 2023 | Allow | 38 | 3 | 1 | No | No |
| 16491866 | CONTRAST MEDIUM FOR MICROANGIOGRAPHY | September 2020 | February 2024 | Abandon | 54 | 2 | 0 | No | No |
| 16978344 | PREPARATION OF SIZE-CONTROLLED MICROVESICLES | September 2020 | May 2023 | Allow | 33 | 3 | 0 | Yes | No |
| 16971545 | METHOD FOR PRODUCING LUMINESCENT PARTICLES, LUMINESCENT PARTICLES, AND BIOIMAGING MATERIAL | August 2020 | March 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 16991404 | ENHANCED SN-38 ANTICANCER AGENT | August 2020 | June 2021 | Allow | 10 | 1 | 0 | No | No |
| 16968766 | TARGETED MICROBUBBLE, PREPARATION METHOD THEREOF, AND USE THEREOF | August 2020 | April 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16987277 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | August 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16943326 | Metal Oxide Nanoparticle-Based Magnetic Resonance Imaging Contrast Agent with a Central Cavity | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16940601 | CONTRAST IMAGING AGENT WITH DISSOLVED GAS-EVOLVING FLUID | July 2020 | October 2022 | Allow | 27 | 1 | 1 | No | No |
| 16964323 | NON-METALLIC MAGNETIC RESONANCE CONTRAST AGENT | July 2020 | May 2023 | Allow | 34 | 1 | 1 | No | No |
| 16935998 | MICROBUBBLE TETHER FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | July 2020 | January 2021 | Allow | 6 | 1 | 0 | No | No |
| 16934414 | 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS | July 2020 | April 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16933198 | Metal Oxide Nanoparticle-Based T1-T2 Dual-Mode Magnetic Resonance Imaging Contrast Agent | July 2020 | August 2021 | Allow | 13 | 1 | 0 | No | No |
| 16922762 | TARGETING LIGANDS FOR TAU PATHOLOGY | July 2020 | October 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16916817 | CONTRAST AGENTS | June 2020 | April 2021 | Allow | 9 | 1 | 0 | No | No |
| 16956995 | ANIONIC CHELATE COMPOUNDS | June 2020 | May 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16771696 | NEW DAZA CHELATORS AS LIGANDS IN LIVER IMAGING | June 2020 | February 2023 | Allow | 32 | 2 | 0 | Yes | No |
| 16887974 | Encapsulation of Microbubbles Within the Aqueous Core of Microcapsules | May 2020 | March 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16867685 | TARGETED GAS-FILLED MICROVESICLES FORMULATION | May 2020 | March 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16761473 | Metal Nanoparticles and Methods of Making Same | May 2020 | April 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16855547 | POSITIVELY CHARGED NANOPARTICLES, USE THEREOF, AND PREPARATION METHOD THEREOF | April 2020 | May 2024 | Allow | 48 | 4 | 0 | Yes | No |
| 16851585 | Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of Cancer | April 2020 | January 2022 | Abandon | 20 | 3 | 0 | No | No |
| 16756433 | SYSTEM AND METHOD TO PROVIDE A CONTRAST AGENT | April 2020 | November 2024 | Allow | 55 | 4 | 1 | Yes | No |
| 16753875 | METHODS AND SYSTEMS FOR PRODUCING, USING, AND ADMINISTERING HYPERPOLARIZED FLUIDS | April 2020 | October 2024 | Allow | 54 | 4 | 1 | No | No |
| 16834871 | Ultrasound Gel Composition | March 2020 | December 2020 | Abandon | 8 | 1 | 0 | No | No |
| 16829498 | METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS | March 2020 | October 2022 | Allow | 31 | 1 | 1 | No | No |
| 16823058 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS | March 2020 | February 2022 | Allow | 23 | 3 | 0 | No | No |
| 16646549 | HYPERPOLARIZED AND DEUTERIUM EXCHANGED HYPERPOLARIZED13C AND 15N-LABELED XANTHINE, ARGININE, GLUTAMINE, AND UREA PROBES | March 2020 | January 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16641773 | HyperPolarising Substrates Through Relayed Transfer Via Systems Containing Exchangeable Protons | February 2020 | June 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16638066 | MAGNETIC STRUCTURES | February 2020 | November 2024 | Abandon | 57 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHLIENTZ, LEAH H.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 7.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SCHLIENTZ, LEAH H works in Art Unit 1618 and has examined 623 patent applications in our dataset. With an allowance rate of 42.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner SCHLIENTZ, LEAH H's allowance rate of 42.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SCHLIENTZ, LEAH H receive 2.42 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SCHLIENTZ, LEAH H is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.1% benefit to allowance rate for applications examined by SCHLIENTZ, LEAH H. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.3% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 74.8% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.